מדינה: ישראל
שפה: עברית
מקור: Ministry of Health
COAGULATION FACTOR II (HUMAN); COAGULATION FACTOR IX (HUMAN- RFIXFC); COAGULATION FACTOR VII (HUMAN); COAGULATION FACTOR X (HUMAN); PROTEIN C; PROTEIN S ANTIGEN
CSL BEHRING LTD., ISRAEL
B02BD01
אבקה וממס להכנת תמיסה להזרקה
COAGULATION FACTOR II (HUMAN) 200 - 480 IU; COAGULATION FACTOR VII (HUMAN) 100 - 250 IU; COAGULATION FACTOR IX (HUMAN- RFIXFC) 200 - 310 IU; COAGULATION FACTOR X (HUMAN) 220 - 600 IU; PROTEIN C 150 - 450 IU; PROTEIN S ANTIGEN 120 - 380 IU
תוך-ורידי
מרשם נדרש
CSL BEHRING GmbH, GERMANY
COAGULATION FACTOR IX, II, VII AND X IN COMBINATION
COAGULATION FACTOR IX, II, VII AND X IN COMBINATION
-Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.
2017-03-31